149 related articles for article (PubMed ID: 37730730)
1. Correspondence on 'Survival outcomes in patients with
Verit FF; Demirkiran F
Int J Gynecol Cancer; 2023 Dec; 33(12):1988. PubMed ID: 37730730
[No Abstract] [Full Text] [Related]
2. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.
Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y
J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes in patients with
Musacchio L; Boccia S; Marchetti C; Minucci A; Camarda F; Cassani C; Ventriglia J; Salutari V; Ghizzoni V; Giudice E; Perri MT; Carbone MV; Ricci C; Pignata S; Fagotti A; Scambia G; Lorusso D
Int J Gynecol Cancer; 2023 Jun; 33(6):922-928. PubMed ID: 36759000
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
5. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
6. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Rusan M; Andersen RF; Jakobsen A; Steffensen KD
Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
[TBL] [Abstract][Full Text] [Related]
7. An Attempt to Stretch the Benefit: Rechallenge with PARP Inhibitors in Ovarian Cancer.
Gonzalez-Ochoa E; Oza AM
Clin Cancer Res; 2023 Jul; 29(14):2563-2566. PubMed ID: 37191665
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Konecny GE; Kristeleit RS
Br J Cancer; 2016 Nov; 115(10):1157-1173. PubMed ID: 27736844
[TBL] [Abstract][Full Text] [Related]
9. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
10. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Della Corte L; Foreste V; Di Filippo C; Giampaolino P; Bifulco G
Expert Opin Investig Drugs; 2021 May; 30(5):543-554. PubMed ID: 33724122
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
[TBL] [Abstract][Full Text] [Related]
13. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
Stewart J; George A; Banerjee S
Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674
[TBL] [Abstract][Full Text] [Related]
14. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
15. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
16. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
17. Epithelial ovarian cancer and brain metastases: might the
Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
[TBL] [Abstract][Full Text] [Related]
18. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
19. BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
Cremona M; Vandenberg CJ; Farrelly AM; Madden SF; Morgan C; Kalachand R; McAlpine JN; Toomey S; Huntsman DG; Grogan L; Breathnach O; Morris P; Carey MS; Scott CL; Hennessy BT
Br J Cancer; 2022 Aug; 127(3):488-499. PubMed ID: 35501389
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]